These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Oxazolidinone structure-activity relationships leading to linezolid. Barbachyn MR; Ford CW Angew Chem Int Ed Engl; 2003 May; 42(18):2010-23. PubMed ID: 12746812 [TBL] [Abstract][Full Text] [Related]
4. The oxazolidinones as a new family of antimicrobial agent. Marchese A; Schito GC Clin Microbiol Infect; 2001; 7 Suppl 4():66-74. PubMed ID: 11688536 [TBL] [Abstract][Full Text] [Related]
5. [Linezolid--new antibacterial agent of the oxazolidinone group: its importance in the control of spreading and treatment of the multidrug resistance gram-positive infections]. Budanov SV; Smirnova LB Antibiot Khimioter; 2002; 47(7):38-42. PubMed ID: 12516195 [No Abstract] [Full Text] [Related]
6. [Linezolid (Zivox), a new highly efficient antibiotic for therapy of Gram-positive infections]. Rebenok ZhA Antibiot Khimioter; 2004; 49(2):26-8. PubMed ID: 15285410 [No Abstract] [Full Text] [Related]
7. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Gonzales RD; Schreckenberger PC; Graham MB; Kelkar S; DenBesten K; Quinn JP Lancet; 2001 Apr; 357(9263):1179. PubMed ID: 11323048 [TBL] [Abstract][Full Text] [Related]
8. In vitro susceptibility of Gram-positive pathogens to linezolid and teicoplanin and effect on outcome in critically ill patients. Wilson AP; Cepeda JA; Hayman S; Whitehouse T; Singer M; Bellingan G J Antimicrob Chemother; 2006 Aug; 58(2):470-3. PubMed ID: 16735420 [TBL] [Abstract][Full Text] [Related]
9. Activity of linezolid against 3,251 strains of uncommonly isolated gram-positive organisms: report from the SENTRY Antimicrobial Surveillance Program. Jones RN; Stilwell MG; Hogan PA; Sheehan DJ Antimicrob Agents Chemother; 2007 Apr; 51(4):1491-3. PubMed ID: 17210770 [TBL] [Abstract][Full Text] [Related]
10. Linezolid. Narang M; Gomber S Indian Pediatr; 2004 Nov; 41(11):1129-32. PubMed ID: 15591662 [TBL] [Abstract][Full Text] [Related]
11. [Therapeutic perspectives of linezolid in the management of infections due to multiresistant Gram-positive pathogens]. Manfredi R Recenti Prog Med; 2007 Mar; 98(3):143-54. PubMed ID: 17484159 [TBL] [Abstract][Full Text] [Related]
12. Rapid emergence of resistance to linezolid during linezolid therapy of an Enterococcus faecium infection. Seedat J; Zick G; Klare I; Konstabel C; Weiler N; Sahly H Antimicrob Agents Chemother; 2006 Dec; 50(12):4217-9. PubMed ID: 16982791 [TBL] [Abstract][Full Text] [Related]
15. Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum Study. Ross JE; Fritsche TR; Sader HS; Jones RN Int J Antimicrob Agents; 2007 Mar; 29(3):295-301. PubMed ID: 17239570 [TBL] [Abstract][Full Text] [Related]
16. In vitro activity of linezolid against Gram-positive isolates causing infection in continuous ambulatory peritoneal dialysis patients. Bowker KE; Wootton M; Holt HA; MacGowan AP J Antimicrob Chemother; 2002 Mar; 49(3):578-80. PubMed ID: 11864965 [No Abstract] [Full Text] [Related]
17. Linezolid for the treatment of resistant gram-positive cocci. Bain KT; Wittbrodt ET Ann Pharmacother; 2001 May; 35(5):566-75. PubMed ID: 11346064 [TBL] [Abstract][Full Text] [Related]